These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27929503)

  • 41. Analysis of direct clinical consequences of MLC positional errors in volumetric-modulated arc therapy using 3D dosimetry system.
    Nithiyanantham K; Mani GK; Subramani V; Mueller L; Palaniappan KK; Kataria T
    J Appl Clin Med Phys; 2015 Sep; 16(5):296–305. PubMed ID: 26699311
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predicting rectal and bladder overdose during the course of prostate radiotherapy using dose-volume data from initial treatment fractions.
    Murthy V; Shukla P; Adurkar P; Master Z; Mahantshetty U; Shrivastava S
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):119-24. PubMed ID: 22300567
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determination of optimal PTV margin for patients receiving CBCT-guided prostate IMRT: comparative analysis based on CBCT dose calculation with four different margins.
    Gill SK; Reddy K; Campbell N; Chen C; Pearson D
    J Appl Clin Med Phys; 2015 Nov; 16(6):252–262. PubMed ID: 26699581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of interfraction prostate motion using megavoltage cone beam computed tomography.
    Bylund KC; Bayouth JE; Smith MC; Hass AC; Bhatia SK; Buatti JM
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):949-56. PubMed ID: 19014783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Applying radiobiological plan ranking methodology to VMAT prostate SBRT.
    Stavrev P; Ruggieri R; Stavreva N; Naccarato S; Alongi F
    Phys Med; 2016 Apr; 32(4):636-41. PubMed ID: 27085287
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Megavoltage cone beam computed tomography dose and the necessity of reoptimization for imaging dose-integrated intensity-modulated radiotherapy for prostate cancer.
    Akino Y; Koizumi M; Sumida I; Takahashi Y; Ogata T; Ota S; Isohashi F; Konishi K; Yoshioka Y
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1715-22. PubMed ID: 21620584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human collagen injections to reduce rectal dose during radiotherapy.
    Noyes WR; Hosford CC; Schultz SE
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1918-22. PubMed ID: 21514738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dosimetric uncertainty in prostate cancer proton radiotherapy.
    Lin L; Vargas C; Hsi W; Indelicato D; Slopsema R; Li Z; Yeung D; Horne D; Palta J
    Med Phys; 2008 Nov; 35(11):4800-7. PubMed ID: 19070212
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitative evaluation of 3D dosimetry for stereotactic volumetric-modulated arc delivery using COMPASS.
    Vikraman S; Manigandan D; Karrthick KP; Sambasivaselli R; Senniandavar V; Ramu M; Rajesh T; Lutz M; Muthukumaran M; Karthikeyan N; Tejinder K
    J Appl Clin Med Phys; 2014 Jan; 16(1):5128. PubMed ID: 25679152
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between pelvic organ-at-risk dose and clinical target volume in postprostatectomy patients receiving intensity-modulated radiotherapy.
    Stanic S; Mathai M; Cui J; Purdy JA; Valicenti RK
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1897-902. PubMed ID: 21536391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Volumetric-modulated arc therapy for stereotactic body radiotherapy of lung tumors: a comparison with intensity-modulated radiotherapy techniques.
    Holt A; van Vliet-Vroegindeweij C; Mans A; Belderbos JS; Damen EM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1560-7. PubMed ID: 21300461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer.
    Hossain S; Xia P; Huang K; Descovich M; Chuang C; Gottschalk AR; Roach M; Ma L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):58-63. PubMed ID: 20133073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo dosimetry for lung radiotherapy including SBRT.
    McCurdy BMC; McCowan PM
    Phys Med; 2017 Dec; 44():123-130. PubMed ID: 28576581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
    Kole TP; Nichols RC; Lei S; Wu B; Huh SN; Morris CG; Lee S; Tong M; Mendenhall NP; Dritschilo A; Collins SP
    Acta Oncol; 2015 Jun; 54(6):825-31. PubMed ID: 25227898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Organ movements and dose exposures in teletherapy of prostate cancer using a rectal balloon.
    Elsayed H; Bölling T; Moustakis C; Müller SB; Schüller P; Ernst I; Willich N; Könemann S
    Strahlenther Onkol; 2007 Nov; 183(11):617-24. PubMed ID: 17960337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interstitial biodegradable balloon for reduced rectal dose during prostate radiotherapy: results of a virtual planning investigation based on the pre- and post-implant imaging data of an international multicenter study.
    Melchert C; Gez E; Bohlen G; Scarzello G; Koziol I; Anscher M; Cytron S; Paz A; Torre T; Bassignani M; Dal Moro F; Jocham D; Yosef RB; Corn BW; Kovács G
    Radiother Oncol; 2013 Feb; 106(2):210-4. PubMed ID: 23484879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vivo rectal wall measurements during HDR prostate brachytherapy with MOSkin dosimeters integrated on a trans-rectal US probe: Comparison with planned and reconstructed doses.
    Carrara M; Tenconi C; Rossi G; Borroni M; Cerrotta A; Grisotto S; Cusumano D; Pappalardi B; Cutajar D; Petasecca M; Lerch M; Gambarini G; Fallai C; Rosenfeld A; Pignoli E
    Radiother Oncol; 2016 Jan; 118(1):148-53. PubMed ID: 26796593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
    Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
    Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimization of collimator parameters to reduce rectal dose in intensity-modulated prostate treatment planning.
    Chapek J; Tobler M; Toy BJ; Lee CM; Leavitt DD
    Med Dosim; 2005; 30(4):205-12. PubMed ID: 16275562
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer.
    Xiang HF; Lu HM; Efstathiou JA; Zietman AL; De Armas R; Harris K; Bloch BN; Qureshi MM; Keohan S; Hirsch AE
    J Appl Clin Med Phys; 2017 May; 18(3):37-43. PubMed ID: 28407345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.